OVERVIEW SARS-COV-2 S1 ANTIBODIES ACE2 ANTIBODIES RESOURCES
Overview

New in vivo study data!

Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.

Twist SARS-CoV-2-S1 Antibodies Syrian Hamster Data

SEE THE DATA

 

Twist Biopharma COVID Antibodies Program

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

We have also developed a set of antibodies targeting the extracellular domain of the ACE2 receptor. These antibodies have high binding affinity and have been demonstrated to inhibit the binding of the S1 protein to ACE2 in vitro.  

All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal as potential candidates for both diagnostic and therapeutic uses.
 

Twist SARS-COV-2 Antibody

NEW – SARS-COV-2 VIRUS NEUTRALIZATION DATA

Explore the data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies targeting the S1 protein of SARS-CoV-2

Review the Data

VHH Data

WRITING THE FUTURE OF COVID-19 THERAPIES

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist covid-19 antibodies

New in vivo study data!

Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.

Twist SARS-CoV-2-S1 Antibodies Syrian Hamster Data

SEE THE DATA

 

Twist Biopharma COVID Antibodies Program

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

We have also developed a set of antibodies targeting the extracellular domain of the ACE2 receptor. These antibodies have high binding affinity and have been demonstrated to inhibit the binding of the S1 protein to ACE2 in vitro.  

All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal as potential candidates for both diagnostic and therapeutic uses.
 

Twist SARS-COV-2 Antibody

NEW – SARS-COV-2 VIRUS NEUTRALIZATION DATA

Explore the data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies targeting the S1 protein of SARS-CoV-2

Review the Data

VHH Data

WRITING THE FUTURE OF COVID-19 THERAPIES

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist covid-19 antibodies

SARS-CoV-2 S1 Antibodies

Twist Anti-SARS-CoV-2 S1 Antibodies

Twist Biopharma’s human antibodies that target the SARS-CoV-2 Spike Protein have a potential dual-purpose and could be developed either for virus neutralization or detection in therapeutic and diagnostic applications, respectively.

Binding curves of the antibody clones to SARS-CoV-2 S1 monomer and trimer
 

Affinity data for individual antibody clones binding of SARS-CoV-2 Spike Glycoprotein S1 or S1 trimer protein. Each clone is indicated with a different color (see legend).

 

S1 Monomer Binding Curve

 

S1 Trimer Binding Curve

Competition assay
 

The S1 antibodies were tested in a cell-based S1-ACE2 competition assay to determine if they showed the ability to block the binding of labeled S1 protein to cells expressing the ACE2 receptor. As shown in the figure below, several antibodies block labeled S1 RBD from binding to ACE2 on the Vero cells: TB182-03, TB182-04, TB182-06, TB182-13 and TB181-63

For more information please review the individual antibodies or antibody panel datasheets.

 

S1 Competition Assay

SPECIFICATIONS

Host Species

Human

Species Reactivity

Reacts with Coronavirus SARS-CoV-2

Panning Antigen

Recombinant fragment SARS-CoV-2 S1 glycoprotein

Database Link

MN908947.3

Clonality

Recombinant Monoclonal

Isotype

Antibodies are human IgG1

Purity

>95% by CE-SDS

Plate Format

Volume 20 µL/well, Concentration 1 mg/mL

Tube Format

Volume 100 μL/tube, Concentration 1 mg/mL
PRODUCT SKUS
Panel
SKU 102895 $12,500
Tube
TB181-13 SKU 103103 $1,000
TB181-03 SKU 103104 $1,000
TB181-04 SKU 103105 $1,000
TB181-08 SKU 103106 $1,000
TB181-63 SKU 103107 $1,000
TB182-13 SKU 103108 $1,000
TB182-03 SKU 103109 $1,000
TB182-04 SKU 103110 $1,000
TB182-06 SKU 103111 $1,000
TB182-07 SKU 103112 $1,000

Order Now

Twist Anti-SARS-CoV-2 S1 Antibodies

Twist Biopharma’s human antibodies that target the SARS-CoV-2 Spike Protein have a potential dual-purpose and could be developed either for virus neutralization or detection in therapeutic and diagnostic applications, respectively.

Binding curves of the antibody clones to SARS-CoV-2 S1 monomer and trimer
 

Affinity data for individual antibody clones binding of SARS-CoV-2 Spike Glycoprotein S1 or S1 trimer protein. Each clone is indicated with a different color (see legend).

 

S1 Monomer Binding Curve

 

S1 Trimer Binding Curve

Competition assay
 

The S1 antibodies were tested in a cell-based S1-ACE2 competition assay to determine if they showed the ability to block the binding of labeled S1 protein to cells expressing the ACE2 receptor. As shown in the figure below, several antibodies block labeled S1 RBD from binding to ACE2 on the Vero cells: TB182-03, TB182-04, TB182-06, TB182-13 and TB181-63

For more information please review the individual antibodies or antibody panel datasheets.

 

S1 Competition Assay

SPECIFICATIONS

Host Species

Human

Species Reactivity

Reacts with Coronavirus SARS-CoV-2

Panning Antigen

Recombinant fragment SARS-CoV-2 S1 glycoprotein

Database Link

MN908947.3

Clonality

Recombinant Monoclonal

Isotype

Antibodies are human IgG1

Purity

>95% by CE-SDS

Plate Format

Volume 20 µL/well, Concentration 1 mg/mL

Tube Format

Volume 100 μL/tube, Concentration 1 mg/mL
PRODUCT SKUS
Panel
SKU 102895 $12,500
Tube
TB181-13 SKU 103103 $1,000
TB181-03 SKU 103104 $1,000
TB181-04 SKU 103105 $1,000
TB181-08 SKU 103106 $1,000
TB181-63 SKU 103107 $1,000
TB182-13 SKU 103108 $1,000
TB182-03 SKU 103109 $1,000
TB182-04 SKU 103110 $1,000
TB182-06 SKU 103111 $1,000
TB182-07 SKU 103112 $1,000

Order Now

ACE2 Antibodies

Twist Human Anti-ACE2 Antibodies

The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic applications.

Kinetic Data
 

The anti-ACE2 antibodies exhibit very high specificity and affinity to their antigen targets with affinities in the picomolar to nanomolar range. The table below lists Fc-capture and direct capture (DC) data from this assay.

 

ACE2 Affinity

Cell Binding Data
 

The entire panel shows varying degrees of specific binding to VERO E6 cells as shown in the table below, and an example of the flow cytometry data for a single clone is also shown. S1 Fc fusion protein and S1 RBD Fc fusion (expressed in-house) were added as positive controls for ACE2 binding.

 

ACE2 MFI

ACE2 MFI Graphs

Competition Assay
 

To assess each antibody clone’s ability to interfere with the binding of the S1 protein to ACE2, serial dilutions of ACE2 were added to biotinylated ACE2 protein. The mixture was then added to SARS-CoV-2 S protein RBD immobilized on an ELISA plate and detected with streptavidin-HRP. Background was subtracted from data points prior to log transformation and curve fitting. IC50 values for all antibody clones are presented in the table.

For more information please review the individual antibodies or antibody panel datasheets.
 

ACE2 Elisa

SPECIFICATIONS

Description

Individual antibody clones that recognize Human ACE2

Host Species

Human

Species Reactivity

Reacts with Human ACE2

Panning Antigen

Recombinant fragment Human ACE2 ECD

Gene ID

59272

Database

NM_001371415

Clonality

Recombinant Monoclonal

Isotype

IgG antibodies are IgG2 and VHH Fc antibodies are IgG1

Purity

>95% by CE-SDS

Plate Format

Volume 20 µL/well, Concentration 1 mg/mL

Tube Format

Volume 100 μL/tube, Concentration 1 mg/mL
PRODUCT SKUS
Panel
SKU 102896 $12,500
Tube
TB183-03 SKU 103091 $1,000
TB183-05 SKU 103092 $1,000
TB183-06 SKU 103093 $1,000
TB183-08 SKU 103094 $1,000
TB184-111 SKU 103095 $1,000
TB184-130 SKU 103096 $1,000
TB184-02 SKU 103097 $1,000
TB184-04 SKU 103098 $1,000
TB184-05 SKU 103099 $1,000
TB184-54 SKU 103100 $1,000
TB184-07 SKU 103101 $1,000
TB184-91 SKU 103102 $1,000

Order Now

Twist Human Anti-ACE2 Antibodies

The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic applications.

Kinetic Data
 

The anti-ACE2 antibodies exhibit very high specificity and affinity to their antigen targets with affinities in the picomolar to nanomolar range. The table below lists Fc-capture and direct capture (DC) data from this assay.

 

ACE2 Affinity

Cell Binding Data
 

The entire panel shows varying degrees of specific binding to VERO E6 cells as shown in the table below, and an example of the flow cytometry data for a single clone is also shown. S1 Fc fusion protein and S1 RBD Fc fusion (expressed in-house) were added as positive controls for ACE2 binding.

 

ACE2 MFI

ACE2 MFI Graphs

Competition Assay
 

To assess each antibody clone’s ability to interfere with the binding of the S1 protein to ACE2, serial dilutions of ACE2 were added to biotinylated ACE2 protein. The mixture was then added to SARS-CoV-2 S protein RBD immobilized on an ELISA plate and detected with streptavidin-HRP. Background was subtracted from data points prior to log transformation and curve fitting. IC50 values for all antibody clones are presented in the table.

For more information please review the individual antibodies or antibody panel datasheets.
 

ACE2 Elisa

PRODUCT SKUS
Panel
SKU 102896 $12,500
Tube
TB183-03 SKU 103091 $1,000
TB183-05 SKU 103092 $1,000
TB183-06 SKU 103093 $1,000
TB183-08 SKU 103094 $1,000
TB184-111 SKU 103095 $1,000
TB184-130 SKU 103096 $1,000
TB184-02 SKU 103097 $1,000
TB184-04 SKU 103098 $1,000
TB184-05 SKU 103099 $1,000
TB184-54 SKU 103100 $1,000
TB184-07 SKU 103101 $1,000
TB184-91 SKU 103102 $1,000

Order Now

SPECIFICATIONS

Description

Individual antibody clones that recognize Human ACE2

Host Species

Human

Species Reactivity

Reacts with Human ACE2

Panning Antigen

Recombinant fragment Human ACE2 ECD

Gene ID

59272

Database

NM_001371415

Clonality

Recombinant Monoclonal

Isotype

IgG antibodies are IgG2 and VHH Fc antibodies are IgG1

Purity

>95% by CE-SDS

Plate Format

Volume 20 µL/well, Concentration 1 mg/mL

Tube Format

Volume 100 μL/tube, Concentration 1 mg/mL
RESOURCES

For more information on Twist’s antibody capabilities

Biopharma Resource Library

 

For more information on Twist’s antibody capabilities

Biopharma Resource Library

 

Additional Information

Please contact the Twist Biopharma team here for information regarding additional antibody information,
requesting larger or custom quantities of antibodies or licensing questions. 

These products are subject to certain use restrictions set forth in Twist’s Supply Terms and Conditions
and Antibody Supplemental Terms and Conditions.

Sensitive, Specific, Potent
Sensitive, Specific, Potent
Sensitive, Specific, Potent